Lilly’s daily GLP-1 pill cut sleep apnea breathing pauses by about 18 an hour

Orforglipron, Eli Lilly’s once-daily GLP-1 pill, reduced the number of breathing interruptions per hour of sleep by about 18 over 52 weeks in adults with obstructive sleep apnea and excess weight. Volunteers given a placebo improved by about 5 an hour. Results were presented on Nov. 9 at the American Heart Association Scientific Sessions in Chicago.

Stay ahead on AI: Join 600,000+ professionals who read The Deep View, the daily newsletter that keeps you up to date with artificial intelligence.

Subscribe to The Deep View →

We may earn a commission if you sign up.

The program, called ATTAIN-OSA, randomized 712 adults in two separate year-long studies at 66 centers across North America, South America, Europe and Asia. Every participant had moderate-to-severe sleep apnea and a body mass index of at least 27, and people with type 1 or type 2 diabetes were excluded. Enrollment ran from October 2024 to July 2026, and the sponsor was Lilly itself, a fact that frames how the numbers should be read.

Two studies, one for CPAP users and one for everyone else

The American Heart Association’s summary of the work splits the 712 participants into 363 adults who did not use continuous positive airway pressure, or CPAP, and 349 current CPAP users. The second group stopped using their machines for seven days before the final overnight sleep test so that the drug’s effect could be measured without the mask. Both studies randomized volunteers one-to-one to orforglipron or a matching placebo, and neither patients nor investigators knew who received which. The AHA release on the results says outcomes were broadly similar whether or not participants used CPAP.

The same design is on file as a Phase 3 master protocol, registered as NCT06649045, with one sub-study for people unable or unwilling to use positive airway pressure and one for people already on it. The registry listing names Eli Lilly and Company as sponsor and requires an apnea-hypopnea index of 15 or higher, the threshold for moderate disease, plus the BMI floor of 27.

Participants averaged about 50 years of age, roughly 30% were women, about 69% were white and 18% Asian, and about 43% identified as Hispanic or Latino. Those proportions matter because sleep apnea is common in many groups that this sample covers only thinly, a limit the investigators acknowledge themselves.

Oxygen, inflammation and blood pressure at 52 weeks

Breathing pauses were not the only measure that moved. Oxygen desaturation dropped 51% on orforglipron versus 18% on placebo in the non-CPAP study, and 44% versus 18% in the CPAP study. The inflammation marker hs-CRP fell 42% versus 4% in the first study and 38% versus 18% in the second. Systolic blood pressure declined by about 7.5 mm Hg versus 1.7 in the first and about 7.0 versus 2.2 in the second, though final pressure readings were taken at week 48 because CPAP was paused before the last sleep study.

Vaishnavi Kundel, M.D., the presenting author and an associate professor of medicine at the Icahn School of Medicine at Mount Sinai, said a convenient daily pill may help expand access to treatment for sleep apnea. She also said that even a modest decrease in blood pressure can help protect a patient’s heart and overall health. Participants reported better sleep too. The most common side effects were nausea, diarrhea and constipation, mostly mild to moderate.

Weight loss as the probable engine, and a tirzepatide precedent

Body weight fell by about 10% to 11% on orforglipron against 1% to 2% on placebo, and the researchers believe weight loss drove much of the apnea benefit, though they have not ruled out other mechanisms. Fat around the upper airway and a heavier neck both narrow the passage during sleep, which is why weight is the best-established lever on the condition.

A different Lilly drug has a head start. In SURMOUNT-OSA, reported by Healio in June 2024, injected tirzepatide lowered the apnea-hypopnea index by 20 events an hour more than placebo in people not using CPAP and by 23.8 more in CPAP users, across 469 adults. Orforglipron’s pooled gap against placebo, roughly 13 an hour by the AHA’s rounded figures, is smaller, but it arrives as a tablet rather than a weekly shot. The pill’s weight-loss profile in obesity was first described in the ATTAIN-1 trial coverage from HCPLive, which reported weight loss of up to 12%. The trial’s master-protocol entry confirms that sleep apnea was a planned indication from the outset.

An abstract, an unapproved drug and a one-year window

The AHA labels the findings preliminary until the full peer-reviewed paper is available, and the association notes that its abstracts are not peer reviewed; a full manuscript was published at the same time in JAMA. Follow-up lasted one year, so nothing is known about long-term cardiovascular outcomes. Some racial and ethnic groups were underrepresented, and orforglipron is described only as a candidate “if approved,” meaning it has no approval for sleep apnea.

The authors say the pill is not meant to replace CPAP. They see it as an add-on for people who use a machine and as an option for those who cannot or will not wear one. Whether regulators accept an approximately 13-per-hour improvement over placebo as enough for an apnea label is the question that Lilly’s filing will eventually answer.

This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.

Stay ahead on AI: Subscribe to The Deep View →

We may earn a commission if you sign up.